Tagged with Global Health

Global Ahead of the 50th anniversary of the World Health Organization’s Model List of Essential Medicines (EML) in 2027, Brendan Shaw explains how the EML has evolved from a basic guide for low-income countries to a global benchmark shaping universal health coverage. Looking at the recently-published 2025 update, Shaw examines the list’s…

Switzerland In a milestone for global health, Novartis has received Swissmedic approval for Coartem Baby, the world’s first antimalarial treatment tailored for newborns and infants under 4.5kg. The decision fills a long-standing therapeutic gap and reinforces the company’s commitment to diseases that fall outside the pharmaceutical industry’s traditional commercial priorities.  …

Switzerland Over the past decade, Dr Lutz Hegemann has helped transform Novartis’ Global Health unit into a strategic pillar that bridges innovation with real-world access. Rather than focusing on visibility, the mandate centres on sustainable impact; embedding access into R&D, rethinking the value of established medicines, and advocating for systemic change…

Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease.   As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…

Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…

Saudi Arabia Despite groundbreaking advances in longevity science, one fundamental challenge remains: how to turn wellness into a scalable, investable industry. Speaking at The Global Healthspan Summit (GHS 2025) in Riyadh, Dr. Mehmood Khan, CEO of the Hevolution Foundation, argues that without a structured economic model, healthy longevity will remain an untapped…

Global Brendan Shaw paints a concerning picture of global health priorities post-pandemic, highlighting the need for renewed focus and investment in healthcare systems to prevent further backsliding.   “There isn’t a financing gap. There is just money that is not moving towards the right things. There’s plenty of money out there”…

IFPMA On Universal Health Coverage day, the Director General of IFPMA (the International Federation of Pharmaceutical Manufacturers and Associations) explains UHC and how the biopharmaceutical industry is part of the solution.   Our industry is much more than a supplier of medicines and vaccines and is increasingly pioneering new ways to overcome…

Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…

Global The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) reflects on 50 years of innovation from the associations…

Mexico The founder and Managing Director of Global Health Intelligence (GHI), Guillaume Corpart highlights the value of competitive intelligence for medical device companies looking to either enter emerging healthcare markets in Latin America and Asia or identify new market opportunities. As an introduction for our readers, Guillaume, could you elaborate on…

pharma The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with international partnerships, but an international institute that is based in France and how if there was one aspect he would…